Latest news and press releases about Immatics N.V. (IMTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials.
Price
| Price | $8.64 |
| Market Cap | $1.2B |
| Exchange | NASDAQ |
| Country | DE |
Valuation Ratios
| Price / Book | 2.45 |
| EV / EBITDA | -4.29 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -47.04% |
| Return on Invested Capital | -52.53% |
| Return on Assets | -42.54% |
| Gross Margin | 100.00% |
| Operating Margin | -543.79% |
| Net Margin | -495.27% |
Related companies: ATAI · CVAC · ELVN · INBX · NKTR · PGEN · RLAY
Explore sector: Healthcare · Biotechnology
More sections of IMTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks